reoperative surgery
Recently Published Documents


TOTAL DOCUMENTS

136
(FIVE YEARS 14)

H-INDEX

20
(FIVE YEARS 2)

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Keouna Pather ◽  
Alexander D. Ghannam ◽  
Shoshana Hacker ◽  
Christina Guerrier ◽  
Erin M. Mobley ◽  
...  

2021 ◽  
Vol 0 ◽  
pp. 0-0
Author(s):  
Timothy F. Tirrell ◽  
Erin R. McNamara ◽  
Belinda H. Dickie

2020 ◽  
Vol 16 (8) ◽  
pp. 983-990 ◽  
Author(s):  
Joel S. Frieder ◽  
Rene Aleman ◽  
Camila Ortiz Gomez ◽  
Francisco Ferri ◽  
Luis Felipe Okida ◽  
...  

2020 ◽  
Vol 2020 (7) ◽  
Author(s):  
Çiğdem Öztürk ◽  
Harald J Hoekstra ◽  
Patrick H J Hemmer ◽  
Jourik A Gietema ◽  
Schelto Kruijff

Abstract Treatment of stage II–IV nonseminomatous testicular germ cell tumors (NSTGCTs) consists of cisplatin-based combination chemotherapy and, when present, resection of residual retroperitoneal tumor mass (RRTM) by conventional laparotomy or laparoscopy. In case of a retroperitoneal recurrence, a second conventional or laparoscopic procedure may be challenging. A case of late relapse after prior conventional resection of a RRTM and tailor-made surgical management with a posterior retroperitoneoscopic resection (PRR) is reported. A posterior retroperitoneoscopic RRTM resection was performed in a 26-year-old male with a history of stage IIC NSTGCT, presenting with a late left-sided retroperitoneal relapse, 6 years after initial treatment. Postoperative course was uneventful and at 1-year follow-up the patient had no evidence of disease. Reoperative surgery by a minimal invasive retroperitoneoscopic approach should be considered as an alternative for patients with a recurrent retroperitoneal tumor mass of a NSTGCT.


Author(s):  
J. James Edelman ◽  
Jaffar M. Khan ◽  
Toby Rogers ◽  
Christian Shults ◽  
Lowell F. Satler ◽  
...  

An increasing number of surgically implanted bioprostheses will require re-intervention for structural valve deterioration. Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) has become an alternative to reoperative surgery, currently approved for high-risk and inoperable patients. Challenges to the technique include higher rates of prosthesis–patient mismatch and coronary obstruction, compared to native valve TAVR. Herein, we review results of ViV TAVR and novel techniques to overcome the aforementioned challenges.


2019 ◽  
Vol 22 (4) ◽  
pp. E281-E282 ◽  
Author(s):  
Shinya Unai ◽  
Vishal Khullar ◽  
Haythem Elgharably ◽  
Jose L Navia

We report a 62-year-old male who had severe aortic insufficiency after a homograft root replacement, requiring venoarterial extracorporeal membrane oxygenation prior to surgery due to profound cardiogenic shock. Severe aortic insufficiency is a contraindication for venoarterial extracorporeal membrane oxygenation, but we were able to stabilize the patient and successfully perform an urgent reoperative surgery.


Sign in / Sign up

Export Citation Format

Share Document